Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Windtree Therapeutics (WINT, $2.50): Critical Aerosurf Phase 2b Trial Completion is Delayed; Can the Company Raise the Capital Needed to Complete the Trial

Overview

Windtree held a conference call on October 25 to update investors on the status of the phase 2a trial of…
Read more…